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Novel Modifiers for Inherited Neurodegenerative Disorders 
- Spinal Muscular Atrophy and Ataxia – 
Neurodegnerative disorders, including autosomal recessive spinal muscular atrophy (SMA), 
amyotrophic lateral sclerosis, Parkinson disease, hereditary spastic paraplegias and ataxias, have been 
shown to share common pathomechanisms, such as endocytic defects and Ca2+ dysregulation. This fact 
highlights the potential of cross-disease modifiers, which specifically modulate these common 
pathways; an example of this phenomena is plastin 3 (PLS3) overexpression, which modulates 
endocytosis. PLS3 overexpression has been identified as a genetic modifier in humans who remained 
unaffected, despite carrying the genetic predisposition for SMA, a detrimental neurodegenerative 
disease and the leading genetic cause of infant lethality. SMA is caused by homozygous deletion or 
mutation of the survival motor neuron 1 (SMN1) gene, whereas SMA disease severity is mainly 
determined by the number of SMN2 copies, a nearly identical copy gene of SMN1, which mainly 
produces aberrantly spliced transcripts. Recently, the first SMA therapy has been approved that is 
based on antisense oligonucleotides (ASO) correcting SMN2 splicing, namely Spinraza. However, for 
severely affected SMA1 individuals - representing 60% of SMA patients - the elevated SMN levels may 
still be insufficient. Thereby, SMN-independent protective modifiers, such as PLS3 overexpression and 
neurocalcin delta (NCALD) reduction, represent an attractive therapeutic target for a combinatorial 
approach. However, the exact underlying mechanism of this protection is largely unknown. In order to 
approach this question and to identify novel modifiers, we focused on PLS3 interacting partners. In 
previous work, we identified calcineurin-like EF-hand protein 1 (CHP1) as a novel direct PLS3 
interacting partner. Remarkably, loss-of function of CHP1 causes autosomal recessive cerebellar ataxia. 
In this context, the aims of this work are the following: 1) analysis of CHP1 reduction as a novel modifier 
of SMA, 2) the identification of common interacting partners of PLS3 and SMN, and 3) analysis of PLS3 
overexpression as a cross-disease modifier for ataxia caused by Chp1 mutation in mice. 
In the first part of this work, we show that the interaction between PLS3 and CHP1 is Ca2+ independent. 
Although CHP1 is ubiquitously present, it is particularly abundant in the central nervous system and at 
SMA relevant sites, including motor neuron (MN) growth cones and neuromuscular junctions (NMJs). 
Hereby, CHP1 is dynamically increasing during neuronal development. Strikingly, we found elevated 
CHP1 levels in spinal cord and brain but not in transversus abdominis muscle of SMA mice. Remarkably, 
CHP1 downregulation restored impaired axonal growth in Smn-depleted NSC34 MN-like cells. 
Congruently, CHP1 overexpression inhibited neurite outgrowth, implying that CHP1 is a negative 
regulator of neurite growth. However, CHP1 reduction, by genetically mutant Chp1 allele, the vacillator 
mutation, did not improve the SMA phenotype of severely-affected SMA mice. Therefore, we aimed 
to test the effect of CHP1 reduction on an intermediate SMA mouse model. Importantly, subcutaneous 
injection of low-dose SMN-ASO in presymptomatic neonatal mice doubled the mean survival span of 
severely-affected SMA mice, while additional CHP1 reduction by heterozygous Chp1 mutation, further 
prolonged the mean survival by 1.6-fold. Strikingly, CHP1 reduction ameliorated well-described 
hallmarks of SMA pathology, including electrophysiological defects, reduced motor axon length, 
reduced number of proprioceptive synapses per MN soma, smaller NMJ size and impaired maturity, as 
well as smaller muscle fibre size, compared to low-dose SMN-ASO alone. Mechanistically, we found 
that Chp1 knockdown in MN-like cells tripled macropinocytosis, whereas clathrin-mediated 
endocytosis (CME) remained unaffected. Thereby, Chp1 knockdown rescued the impaired 
macropinocytosis in Smn-depleted cells. Furthermore, upon Chp1 knockdown we found a significant 
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increase of calcineurin activity. Calcineurin is a Ca2+-calmodulin-dependent phosphatase which 
collectively dephosphorylates proteins involved in endocytosis, whereas calcineurin activity was 
reduced in Smn-depleted cells. In line with this, we showed that dynamin 1 is hyperphosphorylated in 
SMA MNs, which was restored to control level by the heterozygous Chp1 mutant allele. Taken 
together, in this work we conclusively show that CHP1 reduction is a novel SMA modifier, which 
ameliorates hallmarks of SMA pathology by elevating calcineurin phosphatase activity, thereby 
improving impaired endocytosis and eventually neurotransmission. Most importantly, we 
demonstrate that CHP1 reduction is an attractive SMN-independent therapeutic target for a 
combinatorial therapy. 
In the second part of this work, we aimed to investigate in a collaborative work with A. Hart (Brown 
University, Boston, USA) the functional connection between SMN and PLS3. For this purpose, we 
investigated putative common interacting partners of SMN and PLS3. Thereby, we identified 
heterogeneous nuclear ribonuclear protein F (hnRNP F) and H as shared interacting partners by co-
immunoprecipitations and co-localisation analysis. Interestingly, in this context, the Hart laboratory 
showed that the knockdown of sym-2, the ortholog to hnRNP F/H, suppresses endocytic defects in a 
C. elegans SMA model and rescues its neuromuscular defects. These findings contribute to a better 
understanding of the SMN-PLS3 complex and indicate that SMN, PLS3 and hnRNP F/H functionally 
share the endocytic pathway. 
In the last part of this thesis we investigated whether transgenic PLS3 overexpression is a cross-disease 
modifier for autosomal recessive ataxia, caused by loss of CHP1 in the vacillator (vac) mouse model. 
Remarkably, we observed that PLS3 overexpression delays the ataxic gait progression at early disease 
stages but does not rescue it. In line with this, although Purkinje cell axons were still absent, PLS3 
overexpression significantly increased the Purkinje cell number in the cerebellum of 
Chp1vac/vac; PLS3tg/tg mice compared to Chp1vac/vac mice, indicating that PLS3 overexpression delays 
Purkinje cell death in vacillator mice and thereby eventually ameliorates the motor performance at 
early disease stages. First results indicate that PLS3 overexpression most likely improves the previously 
reported impaired NHE1 membrane targeting in the vacillator mouse model, which may ameliorate 
the pH homeostasis, and eventually delays Purkinje cell degeneration. However, further studies are 
crucial to fully understand the underlying mechanism. 
 
